The development of a clinical test to assess the inflammatory phenotype of asthma

The development of a clinical test to assess the inflammatory phenotype of asthma - AIR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38417

Enrollment

115

Registered

2011-09-26

Start date

2012-05-08

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma bronchial hyperreactivity inflammatory lung disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Patients with adult asthma • Age 18-75 • Visiting the outpatient clinic of the UMC and CMH Utrecht • Suitable for sputum induction

Exclusion criteria

Exclusion criteria: • smoking at present or in the last 12 months and/or a past history of more than 10 pack years • antibiotic treatment for a respiratory tract infection

Design outcomes

Primary

Measure	Time frame
To investigate whether analysis of antibodies directed against active β1/β2- integrins (CD29/CD18) and FcγRII (CD32) of primed eosinophils allows the diagnosis of eosinophilic asthma as compared to analysis of sputum eosinophilia.	—

Secondary

Measure	Time frame
1. Measurement of antibodies against active β1/β2-integrins and FcγRII 2. Measuring specific protein profiles in serum of asthma patients by proteomics 3. FeNO measurement	—

Countries

Netherlands

Outcome results